A Medical Device Daily
Elcam Medical (BarAm, Israel) reported that it has acquired a majority interest in privately held Injectech (Loveland, Texas). Terms of the transaction were not disclosed.
Elcam is an OEM supplier of fluid management, drug delivery and vital signs monitoring systems and devices.
Injectech is an OEM provider of luer connectors, barbed fittings, check valves and custom injection molded components to the healthcare industry. It has built a reputation as a flexible, high quality supplier that assists customers on all levels of project management – from prototype to production runs.
"We see great synergy between the two companies and their products. We are impressed with Injectech's reputation among their customer base, especially their quality and responsiveness. Injectech also provides Elcam with a U.S.-based manufacturing operation" said Elcam CEO Ehud Raivitz.
Injectech will operate as an independent entity. Dave Splett and Larry Knipple will continue to manage the operations of Injectech. Lloyd Fishman, Elcam VP, business development & marketing will serve as chairman.
Candela to market laser system in Brazil
Candela (Wayland, Massachusetts) reported that it has received registration approval from the Brazilian National Health Surveillance Agency (ANVISA) to market the Candela Alex TriVantage multi-wavelength, q-switched laser system in Brazil.
"Until now, providing high quality and effective treatment for pigmented lesions and multi-color tattoos meant that Brazilian doctors needed to own at least two different lasers. With Alex TriVantage's Laser-Pumped-Laser (LPL) technology, a greater number of doctors will be able to offer a wider variety of services assured of the ability to provide treatment regardless of the patient's skin color," said Candela President/CEO, Gerard Puorro. "This approval increases the number of Candela products marketed in Brazil, enabling us to offer a more complete range of highly effective aesthetic laser solutions."
Q-switched Laser-Pumped-Laser (LPL) technology provides 755 nm, 532 nm and 1064 nm output wavelengths, making Alex TriVantage extremely versatile. The addition of a long-pulse mode at 755nm offers advanced treatments for a wider variety of pigmented lesions without side effects.
PathoLase submits new foot treatment
PathoLase (Chico, California) said it has received approval from the Therapeutic Goods Administration (TGA) for its new PinPointe FootLaser treatment for toenail fungus (Onychomycosis), certifying it has met the TGA's consumer and health safety standards and can be offered by certified healthcare providers throughout Australia and New Zealand.
The PathoLase PinPointe FootLaser uses laser technology to target the pathogens that cause toenail fungus. PinPointe's laser light passes through the toenail without causing damage to the nail or surrounding skin. Following the procedure, the new nail will grow in healthy and clear.
1st Zoll AutoPulse installed in New Zealand
Zoll Medical (Chelmsford, Massachusetts) a manufacturer of resuscitation devices and related software solutions, reported that the Taranaki District Health Board Ambulance (TDHB) Service in Plymouth is the first service in New Zealand to install the Zoll AutoPulse non-invasive cardiac support pump, which was used by paramedics to save the life of a 69-year-old woman experiencing sudden cardiac arrest (SCA) two weeks after installation.
According to Ian May, TDHB ambulance manager, the 69-year-old was discharged from the hospital after surviving sudden cardiac arrest. "We used the AutoPulse on her two or three times for about five minutes each when she re-arrested and were able to restore her pulse," he said. "This device contributes significantly to the total management of critical care. It frees staff to concentrate on other aspects of resuscitating the patient, such as defibrillation, airway management, intubation, and drug therapy."
According to the company, the pump is an automated, portable device with an easy-to-use, load-distributing LifeBand that squeezes the entire chest, improving blood flow to the heart and brain during SCA. The AutoPulse offers a significant advantage over manual CPR in that it can move blood more effectively than manual chest compressions.